Global Myasthenia Gravis Disease Drugs Market Size, Status and Forecast 2019-2025

重症筋無力症薬の世界市場:規模・現状・予測2019-2025

◆タイトル:Global Myasthenia Gravis Disease Drugs Market Size, Status and Forecast 2019-2025
◆商品コード:DATA908B00781
◆調査・発行会社:QYResearch
◆発行日:2019年8月20日
◆ページ数:90
◆レポート形式:(印刷可能)PDF / 英語
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥421,200見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥842,400見積依頼/購入/質問フォーム
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常2日~3日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearchの日本における正規販売代理店です。

【レポートの概要】

※当調査レポートでは、重症筋無力症薬の世界市場について調査・分析し、重症筋無力症薬の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別(アセチルコリンエステラーゼ阻害剤、免疫抑制薬、ステロイド、その他)、用途別(病院、診療所、その他)、地域別(北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米)に区分して市場規模を算出しました。


・レポートの概要
・世界の重症筋無力症薬市場動向
・主要企業別マーケットシェア
・重症筋無力症薬の種類別市場規模2014-2019
(アセチルコリンエステラーゼ阻害剤、免疫抑制薬、ステロイド、その他)
・重症筋無力症薬の用途別市場規模2014-2019
(病院、診療所、その他)
・重症筋無力症薬の北米市場:主要企業・種類別/用途別市場規模
・重症筋無力症薬のヨーロッパ市場:主要企業・種類別/用途別市場規模
・重症筋無力症薬の中国市場:主要企業・種類別/用途別市場規模
・重症筋無力症薬の日本国内市場:主要企業・種類別/用途別市場規模
・重症筋無力症薬の東南アジア市場:主要企業・種類別/用途別市場規模
・重症筋無力症薬のインド市場:主要企業・種類別/用途別市場規模
・重症筋無力症薬の中南米市場:主要企業・種類別/用途別市場規模
・主要企業のプロフィール
(GlaxoSmithKline、Novartis、Teva Pharmaceutical、Roche、Bristol-Myers Squibb、Apotex、Cipla、Biogen、AbbVie、Valeant Pharmaceuticals、Sun Pharmaceuticals)
・重症筋無力症薬の市場規模予測2019-2025
(種類別、用途別、地域別市場予測)
・アナリストの観点・結論
...

Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.The Americas accounted for the largest market share of the global myasthenia gravis disease market owing to the growing number of drug manufacturers, increasing awareness about the long-term effects of muscle dystrophy, and rising government funding for the treatment of this disease in the region. Moreover, the U.S. contributes to a significant market share in the global pharmaceutical industry.
In 2018, the global Myasthenia Gravis Disease Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Myasthenia Gravis Disease Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Myasthenia Gravis Disease Drugs development in United States, Europe and China.

The key players covered in this study
GlaxoSmithKline
Novartis
Teva Pharmaceutical
Roche
Bristol-Myers Squibb
Apotex
Cipla
Biogen
AbbVie
Valeant Pharmaceuticals
Sun Pharmaceuticals

Market segment by Type, the product can be split into
Acetylcholinesterase Inhibitors
Immunosuppressant Drugs
Steroid
Others

Market segment by Application, split into
Hospitals
Clinics
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Myasthenia Gravis Disease Drugs status, future forecast, growth opportunity, key market and key players.
To present the Myasthenia Gravis Disease Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Myasthenia Gravis Disease Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Myasthenia Gravis Disease Drugs Market Size Growth Rate by Type (2014-2025)
1.4.2 Acetylcholinesterase Inhibitors
1.4.3 Immunosuppressant Drugs
1.4.4 Steroid
1.4.5 Others
1.5 Market by Application
1.5.1 Global Myasthenia Gravis Disease Drugs Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Myasthenia Gravis Disease Drugs Market Size
2.2 Myasthenia Gravis Disease Drugs Growth Trends by Regions
2.2.1 Myasthenia Gravis Disease Drugs Market Size by Regions (2014-2025)
2.2.2 Myasthenia Gravis Disease Drugs Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Myasthenia Gravis Disease Drugs Market Size by Manufacturers
3.1.1 Global Myasthenia Gravis Disease Drugs Revenue by Manufacturers (2014-2019)
3.1.2 Global Myasthenia Gravis Disease Drugs Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Myasthenia Gravis Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Myasthenia Gravis Disease Drugs Key Players Head office and Area Served
3.3 Key Players Myasthenia Gravis Disease Drugs Product/Solution/Service
3.4 Date of Enter into Myasthenia Gravis Disease Drugs Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Myasthenia Gravis Disease Drugs Market Size by Type (2014-2019)
4.2 Global Myasthenia Gravis Disease Drugs Market Size by Application (2014-2019)

5 United States
5.1 United States Myasthenia Gravis Disease Drugs Market Size (2014-2019)
5.2 Myasthenia Gravis Disease Drugs Key Players in United States
5.3 United States Myasthenia Gravis Disease Drugs Market Size by Type
5.4 United States Myasthenia Gravis Disease Drugs Market Size by Application

6 Europe
6.1 Europe Myasthenia Gravis Disease Drugs Market Size (2014-2019)
6.2 Myasthenia Gravis Disease Drugs Key Players in Europe
6.3 Europe Myasthenia Gravis Disease Drugs Market Size by Type
6.4 Europe Myasthenia Gravis Disease Drugs Market Size by Application

7 China
7.1 China Myasthenia Gravis Disease Drugs Market Size (2014-2019)
7.2 Myasthenia Gravis Disease Drugs Key Players in China
7.3 China Myasthenia Gravis Disease Drugs Market Size by Type
7.4 China Myasthenia Gravis Disease Drugs Market Size by Application

8 Japan
8.1 Japan Myasthenia Gravis Disease Drugs Market Size (2014-2019)
8.2 Myasthenia Gravis Disease Drugs Key Players in Japan
8.3 Japan Myasthenia Gravis Disease Drugs Market Size by Type
8.4 Japan Myasthenia Gravis Disease Drugs Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Myasthenia Gravis Disease Drugs Market Size (2014-2019)
9.2 Myasthenia Gravis Disease Drugs Key Players in Southeast Asia
9.3 Southeast Asia Myasthenia Gravis Disease Drugs Market Size by Type
9.4 Southeast Asia Myasthenia Gravis Disease Drugs Market Size by Application

10 India
10.1 India Myasthenia Gravis Disease Drugs Market Size (2014-2019)
10.2 Myasthenia Gravis Disease Drugs Key Players in India
10.3 India Myasthenia Gravis Disease Drugs Market Size by Type
10.4 India Myasthenia Gravis Disease Drugs Market Size by Application

11 Central & South America
11.1 Central & South America Myasthenia Gravis Disease Drugs Market Size (2014-2019)
11.2 Myasthenia Gravis Disease Drugs Key Players in Central & South America
11.3 Central & South America Myasthenia Gravis Disease Drugs Market Size by Type
11.4 Central & South America Myasthenia Gravis Disease Drugs Market Size by Application

12 International Players Profiles
12.1 GlaxoSmithKline
12.1.1 GlaxoSmithKline Company Details
12.1.2 Company Description and Business Overview
12.1.3 Myasthenia Gravis Disease Drugs Introduction
12.1.4 GlaxoSmithKline Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)
12.1.5 GlaxoSmithKline Recent Development
12.2 Novartis
12.2.1 Novartis Company Details
12.2.2 Company Description and Business Overview
12.2.3 Myasthenia Gravis Disease Drugs Introduction
12.2.4 Novartis Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)
12.2.5 Novartis Recent Development
12.3 Teva Pharmaceutical
12.3.1 Teva Pharmaceutical Company Details
12.3.2 Company Description and Business Overview
12.3.3 Myasthenia Gravis Disease Drugs Introduction
12.3.4 Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)
12.3.5 Teva Pharmaceutical Recent Development
12.4 Roche
12.4.1 Roche Company Details
12.4.2 Company Description and Business Overview
12.4.3 Myasthenia Gravis Disease Drugs Introduction
12.4.4 Roche Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)
12.4.5 Roche Recent Development
12.5 Bristol-Myers Squibb
12.5.1 Bristol-Myers Squibb Company Details
12.5.2 Company Description and Business Overview
12.5.3 Myasthenia Gravis Disease Drugs Introduction
12.5.4 Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)
12.5.5 Bristol-Myers Squibb Recent Development
12.6 Apotex
12.6.1 Apotex Company Details
12.6.2 Company Description and Business Overview
12.6.3 Myasthenia Gravis Disease Drugs Introduction
12.6.4 Apotex Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)
12.6.5 Apotex Recent Development
12.7 Cipla
12.7.1 Cipla Company Details
12.7.2 Company Description and Business Overview
12.7.3 Myasthenia Gravis Disease Drugs Introduction
12.7.4 Cipla Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)
12.7.5 Cipla Recent Development
12.8 Biogen
12.8.1 Biogen Company Details
12.8.2 Company Description and Business Overview
12.8.3 Myasthenia Gravis Disease Drugs Introduction
12.8.4 Biogen Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)
12.8.5 Biogen Recent Development
12.9 AbbVie
12.9.1 AbbVie Company Details
12.9.2 Company Description and Business Overview
12.9.3 Myasthenia Gravis Disease Drugs Introduction
12.9.4 AbbVie Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)
12.9.5 AbbVie Recent Development
12.10 Valeant Pharmaceuticals
12.10.1 Valeant Pharmaceuticals Company Details
12.10.2 Company Description and Business Overview
12.10.3 Myasthenia Gravis Disease Drugs Introduction
12.10.4 Valeant Pharmaceuticals Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)
12.10.5 Valeant Pharmaceuticals Recent Development
12.11 Sun Pharmaceuticals

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

List of Tables and Figures

Table Myasthenia Gravis Disease Drugs Key Market Segments
Table Key Players Myasthenia Gravis Disease Drugs Covered
Table Global Myasthenia Gravis Disease Drugs Market Size Growth Rate by Type 2014-2025 (Million US$)
Figure Global Myasthenia Gravis Disease Drugs Market Size Market Share by Type 2014-2025
Figure Acetylcholinesterase Inhibitors Figures
Table Key Players of Acetylcholinesterase Inhibitors
Figure Immunosuppressant Drugs Figures
Table Key Players of Immunosuppressant Drugs
Figure Steroid Figures
Table Key Players of Steroid
Figure Others Figures
Table Key Players of Others
Table Global Myasthenia Gravis Disease Drugs Market Size Growth by Application 2014-2025 (Million US$)
Figure Hospitals Case Studies
Figure Clinics Case Studies
Figure Others Case Studies
Figure Myasthenia Gravis Disease Drugs Report Years Considered
Table Global Myasthenia Gravis Disease Drugs Market Size 2014-2025 (Million US$)
Figure Global Myasthenia Gravis Disease Drugs Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Myasthenia Gravis Disease Drugs Market Size by Regions 2014-2025 (Million US$)
Table Global Myasthenia Gravis Disease Drugs Market Size by Regions 2014-2019 (Million US$)
Table Global Myasthenia Gravis Disease Drugs Market Share by Regions 2014-2019
Figure Global Myasthenia Gravis Disease Drugs Market Share by Regions 2014-2019
Figure Global Myasthenia Gravis Disease Drugs Market Share by Regions 2019
Table Market Top Trends
Table Global Myasthenia Gravis Disease Drugs Revenue by Manufacturers (2014-2019) (Million US$)
Table Global Myasthenia Gravis Disease Drugs Market Share by Manufacturers (2014-2019)
Figure Global Myasthenia Gravis Disease Drugs Market Share by Manufacturers in 2018
Table Global Myasthenia Gravis Disease Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Myasthenia Gravis Disease Drugs Product/Solution/Service
Table Date of Enter into Myasthenia Gravis Disease Drugs Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Myasthenia Gravis Disease Drugs Market Size by Type (2014-2019) (Million US$)
Table Global Myasthenia Gravis Disease Drugs Market Size Share by Type (2014-2019)
Figure Global Myasthenia Gravis Disease Drugs Market Size Market Share by Type (2014-2019)
Table Global Myasthenia Gravis Disease Drugs Market Size by Application (2014-2019) (Million US$)
Table Global Myasthenia Gravis Disease Drugs Market Size Share by Application (2014-2019)
Figure Global Myasthenia Gravis Disease Drugs Market Size Market Share by Application (2014-2019)
Figure Global Myasthenia Gravis Disease Drugs Revenue Market Share by Application in 2018
Figure United States Myasthenia Gravis Disease Drugs Market Size 2014-2019 (Million US$)
Table United States Key Players Myasthenia Gravis Disease Drugs Revenue (2018-2019) (Million US$)
Table United States Key Players Myasthenia Gravis Disease Drugs Market Share (2018-2019)
Table United States Myasthenia Gravis Disease Drugs Market Size by Type (2014-2019) (Million US$)
Table United States Myasthenia Gravis Disease Drugs Market Share by Type (2014-2019)
Table United States Myasthenia Gravis Disease Drugs Market Size by Application (2014-2019) (Million US$)
Table United States Myasthenia Gravis Disease Drugs Market Share by Application (2014-2019)
Figure Europe Myasthenia Gravis Disease Drugs Market Size 2014-2019 (Million US$)
Table Europe Key Players Myasthenia Gravis Disease Drugs Revenue (2018-2019) (Million US$)
Table Europe Key Players Myasthenia Gravis Disease Drugs Market Share (2018-2019)
Table Europe Myasthenia Gravis Disease Drugs Market Size by Type (2014-2019) (Million US$)
Table Europe Myasthenia Gravis Disease Drugs Market Share by Type (2014-2019)
Table Europe Myasthenia Gravis Disease Drugs Market Size by Application (2014-2019) (Million US$)
Table Europe Myasthenia Gravis Disease Drugs Market Share by Application (2014-2019)
Figure China Myasthenia Gravis Disease Drugs Market Size 2014-2019 (Million US$)
Table China Key Players Myasthenia Gravis Disease Drugs Revenue (2018-2019) (Million US$)
Table China Key Players Myasthenia Gravis Disease Drugs Market Share (2018-2019)
Table China Myasthenia Gravis Disease Drugs Market Size by Type (2014-20189) (Million US$)
Table China Myasthenia Gravis Disease Drugs Market Share by Type (2014-2019)
Table China Myasthenia Gravis Disease Drugs Market Size by Application (2014-2019) (Million US$)
Table China Myasthenia Gravis Disease Drugs Market Share by Application (2014-2019)
Figure Japan Myasthenia Gravis Disease Drugs Market Size 2014-2019 (Million US$)
Table Japan Key Players Myasthenia Gravis Disease Drugs Revenue (2018-2019) (Million US$)
Table Japan Key Players Myasthenia Gravis Disease Drugs Market Share (2018-2019)
Table Japan Myasthenia Gravis Disease Drugs Market Size by Type (2014-2019) (Million US$)
Table Japan Myasthenia Gravis Disease Drugs Market Share by Type (2014-2019)
Table Japan Myasthenia Gravis Disease Drugs Market Size by Application (2014-2019) (Million US$)
Table Japan Myasthenia Gravis Disease Drugs Market Share by Application (2014-2019)
Figure Southeast Asia Myasthenia Gravis Disease Drugs Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Myasthenia Gravis Disease Drugs Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Myasthenia Gravis Disease Drugs Market Share (2018-2019)
Table Southeast Asia Myasthenia Gravis Disease Drugs Market Size by Type (2014-2019) (Million US$)
Table Southeast Asia Myasthenia Gravis Disease Drugs Market Share by Type (2014-2019)
Table Southeast Asia Myasthenia Gravis Disease Drugs Market Size by Application (2014-2019) (Million US$)
Table Southeast Asia Myasthenia Gravis Disease Drugs Market Share by Application (2014-2019)
Figure India Myasthenia Gravis Disease Drugs Market Size 2014-2019 (Million US$)
Table India Key Players Myasthenia Gravis Disease Drugs Revenue (2018-2019) (Million US$)
Table India Key Players Myasthenia Gravis Disease Drugs Market Share (2018-2019)
Table India Myasthenia Gravis Disease Drugs Market Size by Type (2014-2019) (Million US$)
Table India Myasthenia Gravis Disease Drugs Market Share by Type (2014-2019)
Table India Myasthenia Gravis Disease Drugs Market Size by Application (2014-2019) (Million US$)
Table India Myasthenia Gravis Disease Drugs Market Share by Application (2014-2019)
Figure Central & South America Myasthenia Gravis Disease Drugs Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Myasthenia Gravis Disease Drugs Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Myasthenia Gravis Disease Drugs Market Share (2018-2019)
Table Central & South America Myasthenia Gravis Disease Drugs Market Size by Type (2014-2019) (Million US$)
Table Central & South America Myasthenia Gravis Disease Drugs Market Share by Type (2014-2019)
Table Central & South America Myasthenia Gravis Disease Drugs Market Size by Application (2014-2019) (Million US$)
Table Central & South America Myasthenia Gravis Disease Drugs Market Share by Application (2014-2019)
Table GlaxoSmithKline Company Details
Table GlaxoSmithKline Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019) (Million US$)
Figure GlaxoSmithKline Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2014-2019)
Table GlaxoSmithKline Recent Development
Table Novartis Company Details
Table Novartis Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)(Million US$)
Figure Novartis Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2014-2019)
Table Novartis Recent Development
Table Teva Pharmaceutical Company Details
Table Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)(Million US$)
Figure Teva Pharmaceutical Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2014-2019)
Table Teva Pharmaceutical Recent Development
Table Roche Company Details
Table Roche Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)(Million US$)
Figure Roche Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2014-2019)
Table Roche Recent Development
Table Bristol-Myers Squibb Company Details
Table Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)(Million US$)
Figure Bristol-Myers Squibb Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2014-2019)
Table Bristol-Myers Squibb Recent Development
Table Apotex Company Details
Table Apotex Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)(Million US$)
Figure Apotex Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2014-2019)
Table Apotex Recent Development
Table Cipla Company Details
Table Cipla Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)(Million US$)
Figure Cipla Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2014-2019)
Table Cipla Recent Development
Table Biogen Company Details
Table Biogen Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)(Million US$)
Figure Biogen Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2014-2019)
Table Biogen Recent Development
Table AbbVie Company Details
Table AbbVie Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)(Million US$)
Figure AbbVie Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2014-2019)
Table AbbVie Recent Development
Table Valeant Pharmaceuticals Company Details
Table Valeant Pharmaceuticals Revenue in Myasthenia Gravis Disease Drugs Business (2014-2019)(Million US$)
Figure Valeant Pharmaceuticals Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2014-2019)
Table Valeant Pharmaceuticals Recent Development
Table Sun Pharmaceuticals Company Details
Table Global Myasthenia Gravis Disease Drugs Market Size by Regions (Million US$) 2019-2025
Figure Global Myasthenia Gravis Disease Drugs Market Size Share by Regions (2019-2025)
Figure Global Myasthenia Gravis Disease Drugs Market Size Share by Regions in 2025
Figure United States Myasthenia Gravis Disease Drugs Market Size Forecast (2019-2025)(Million USD)
Figure Europe Myasthenia Gravis Disease Drugs Market Size Forecast (2019-2025)(Million USD)
Figure China Myasthenia Gravis Disease Drugs Market Size Forecast (2019-2025)(Million USD)
Figure Japan Myasthenia Gravis Disease Drugs Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Myasthenia Gravis Disease Drugs Market Size Forecast (2019-2025)(Million USD)
Figure India Myasthenia Gravis Disease Drugs Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Myasthenia Gravis Disease Drugs Market Size Forecast (2019-2025)(Million USD)
Table Global Myasthenia Gravis Disease Drugs Market Size by Product (2019-2025) (Million US$)
Figure Global Myasthenia Gravis Disease Drugs Market Size by Product (2019-2025)
Figure Global Myasthenia Gravis Disease Drugs Market Size by Product in 2025
Table Global Myasthenia Gravis Disease Drugs Market Size by Application (2019-2025) (Million US$)
Figure Global Myasthenia Gravis Disease Drugs Market Size by Application (2019-2025)
Figure Global Myasthenia Gravis Disease Drugs Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[重症筋無力症薬の世界市場:規模・現状・予測2019-2025] (Global Myasthenia Gravis Disease Drugs Market Size, Status and Forecast 2019-2025 / DATA908B00781)についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆